Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Ab...

por Smolen, Josef S., Wollenhaupt, Jürgen, Gomez-Reino, Juan J., Grassi, Walter, Gaillez, Corine, Poncet, Coralie, Le Bars, Manuela, Westhovens, Rene
Publicado 2015

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis

por D’Agostino, Maria-Antonietta, Alten, Rieke, Mysler, Eduardo, Le Bars, Manuela, Ye, June, Murthy, Bindu, Heitzmann, Julia, Vadanici, Radu, Ferraccioli, Gianfranco
Publicado 2017

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, pro...

por Alten, Rieke, Nüßlein, Hubert G, Mariette, Xavier, Galeazzi, Mauro, Lorenz, Hanns-Martin, Cantagrel, Alain, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, Le Bars, Manuela
Publicado 2017

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study

por Alten, Rieke, Mariette, Xavier, Lorenz, Hanns-Martin, Galeazzi, Mauro, Cantagrel, Alain, Nüßlein, Hubert G, Chartier, Melanie, Elbez, Yedid, Rauch, Christiane, Le Bars, Manuela
Publicado 2017

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial

por McInnes, Iain B, Ferraccioli, Gianfranco, D'Agostino, Maria-Antonietta, Le Bars, Manuela, Banerjee, Subhashis, Ahmad, Harris A, Elbez, Yedid, Mease, Philip J
Publicado 2019

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sust...

por Jansen, Diahann T S L, Emery, Paul, Smolen, Josef S, Westhovens, Rene, Le Bars, Manuela, Connolly, Sean E, Ye, June, Toes, René E M, Huizinga, Tom W J
Publicado 2018

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

por Panés, Julian, Vermeire, Séverine, D'Haens, Geert R., Danese, Silvio, Magro, Fernando, Nazar, Maciej, Le Bars, Manuela, Lahaye, Marjolein, Ni, Lioudmila, Bravatà, Ivana, Gaya, Daniel R., Peyrin‐Biroulet, Laurent, Dignass, Axel
Publicado 2023

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

por Schiff, Michael, Keiserman, Mauro, Codding, Christine, Songcharoen, Suthin, Berman, Alberto, Nayiager, Sauithree, Saldate, Cristina, Aranda, Richard, Becker, Jean-Claude, Nys, Marleen, le Bars, Manuela, Reed, Diane Moniz, Poncet, Coralie, Dougados, Maxime
Publicado 2011

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised...

por Conaghan, Philip G, Durez, Patrick, Alten, Rieke E, Burmester, Gerd-Rüdiger, Tak, Paul P, Klareskog, Lars, Catrina, Anca Irinel, DiCarlo, Julie, Gaillez, Corine, Le Bars, Manuela, Zhou, Xianhuang, Peterfy, Charles
Publicado 2013

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study

por D'Agostino, Maria-Antonietta, Boers, Maarten, Wakefield, Richard J, Berner Hammer, Hilde, Vittecoq, Olivier, Filippou, Georgios, Balint, Peter, Möller, Ingrid, Iagnocco, Annamaria, Naredo, Esperanza, Østergaard, Mikkel, Gaillez, Corine, Le Bars, Manuela
Publicado 2016

Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data

por Zhuleku, Evi, Antolin-Fontes, Beatriz, Borsi, Andras, Nissinen, Riikka, Bravatà, Ivana, Barthelmes, Jennifer Norma, Le Bars, Manuela, Lee, Jennifer, Passey, Alun, Maywald, Ulf, Deiters, Barthold, Bokemeyer, Bernd, Wilke, Thomas, Ghiani, Marco
Publicado 2022

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

por Nüßlein, Hubert G., Alten, Rieke, Galeazzi, Mauro, Lorenz, Hanns-Martin, Nurmohamed, Michael T., Bensen, William G., Burmester, Gerd R., Peter, Hans-Hartmut, Pavelka, Karel, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, Le Bars, Manuela
Publicado 2015

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study

por Alten, Rieke, Nüßlein, Hubert, Galeazzi, Mauro, Lorenz, Hanns-Martin, Nurmohamed, Michael T, Bensen, William G, Burmester, Gerd R, Peter, Hans-Hartmut, Pavelka, Karel, Chartier, Mélanie, Poncet, Coralie, Rauch, Christiane, Elbez, Yedid, Le Bars, Manuela
Publicado 2016

Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE stud...

por D'Agostino, Maria-Antonietta, Wakefield, Richard J, Berner-Hammer, Hilde, Vittecoq, Olivier, Filippou, Georgios, Balint, Peter, Möller, Ingrid, Iagnocco, Annamaria, Naredo, Esperanza, Østergaard, Mikkel, Boers, Maarten, Gaillez, Corine, Van Holder, Karina, Le Bars, Manuela
Publicado 2016